Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The clinical benefit of imaging striatal dopamine transporters with [I-123]FP-CIT SPET in differentiating patients with presynaptic parkinsonism fromthose with other forms of parkinsonism
Autore:
Booij, J; Speelman, JD; Horstink, MWIM; Wolters, EC;
Indirizzi:
Univ Amsterdam, Dept Nucl Med, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands NL-1105 AZ Z Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands ept Neurol, Amsterdam, Netherlands Univ Nijmegen Hosp, Dept Neurol, NL-6500 HB Nijmegen, Netherlands Univ Nijmegen Hosp Nijmegen Netherlands NL-6500 HB Nijmegen, Netherlands Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Neurol, Grad Sch Neurosci, Amsterdam, Netherlands Vrije Univ Amsterdam Amsterdam Netherlands osci, Amsterdam, Netherlands
Titolo Testata:
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
fascicolo: 3, volume: 28, anno: 2001,
pagine: 266 - 272
SICI:
0340-6997(200103)28:3<266:TCBOIS>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON-EMISSION-TOMOGRAPHY; MULTIPLE SYSTEM ATROPHY; PROGRESSIVE SUPRANUCLEAR PALSY; RICHARDSON-OLSZEWSKI-SYNDROME; I-123 BETA-CIT; DISEASE; DIAGNOSIS; BINDING; ANALOGS; PET;
Keywords:
parkinsonism; [I-123]FP-CIT SPET; dopamine transporter; clinical follow-up;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Booij, J Univ Amsterdam, Dept Nucl Med, Grad Sch Neurosci, F2 N,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands Univ Amsterdam F2 N,Meibergdreef 9 Amsterdam Netherlands NL-1105 AZ
Citazione:
J. Booij et al., "The clinical benefit of imaging striatal dopamine transporters with [I-123]FP-CIT SPET in differentiating patients with presynaptic parkinsonism fromthose with other forms of parkinsonism", EUR J NUCL, 28(3), 2001, pp. 266-272

Abstract

[I-123]FP-CIT (N-omega -fluoropropyl-2 beta -carbomethoxy-3 beta-{4-iodophenyl}nortropane) has been developed successfully as a radioligand for single-photon emission tomography (SPET) imaging of dopamine transporters, whichare situated in the membrane of dopaminergic neurons. Imaging of these transporters has shown promise as a clinical tool to detect degeneration of the dopaminergic nigrostriatal pathway. Several "presynaptic parkinsonian" syndromes, such as Parkinson's disease or multiple system atrophy, are characterised by degeneration of the nigrostriatal pathway. [I-123]FP-CIT SPET imaging studies have shown the ability to detect loss of striatal dopamine transporters in such syndromes. However, in clinical practice it is sometimesdifficult, but important, to discriminate patients with "presynaptic parkinsonism" from those with other forms of parkinsonism not characterised by loss of presynaptic dopaminergic cells (e.g. psychogenic parkinsonism or drug-induced postsynaptic parkinsonism). In these inconclusive cases, it may be of value to confirm or exclude the existence of degeneration of nigrostriatal dopaminergic cells by using imaging techniques such as [I-123]FP-CIT SPET. Using [I-123]FP-CIT SPET, we have imaged the striatal dopamine transporters in a group of patients with inconclusive forms of parkinsonism, and, moreover, have been able to perform clinical follow-up of these patients 2-4 years after imaging. In 33 inconclusive cases, ratios of specific to non-specific binding were calculated for the caudate nucleus and putamen following [I-123]FP-CIT SPET imaging and compared with ratios obtained in healthycontrols. In nine of the patients, degeneration of the nigrostriatal pathway was found scintigraphically and in all these cases, presynaptic parkinsonism was confirmed by clinical follow-up, In the other 24 subjects no degeneration was found scintigraphically, Forms of parkinsonism other than the presynaptic were confirmed at follow-up in 19 cases, and in three cases no conclusive diagnosis was established, but presynaptic parkinsonism was excluded clinically. A clinical diagnosis of presynaptic parkinsonism was established in two cases: one case of multiple system atrophy tin this patient loss of dopamine D-2 receptors was found with [I-123]iodobenzamide SPET performed 2 weeks after [I-123]FP-CIT imaging) and one case of Parkinson's disease. Our data suggest that the positive predictive value of [I-123]FP-CIT imaging is very high, and although the negative predictive value is lower, dopamine transporter imaging offers the prospect of a quick, objective methodto confirm or exclude presynaptic parkinsonism in inconclusive cases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/09/19 alle ore 19:07:57